Document is current

Article History

Received: 10 December 2024

Accepted: 23 January 2025

First Online: 6 February 2025

Declarations

:

: Approval for the study was granted by the Ethics Committee of Keio University School of Medicine (Approval number: 20140335). The study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all the participants.

: Not applicable.

: M.A. has received speaking fees from AbbVie, Asahi-Kasei, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Taisho, UCB, Gilead Sciences, Glaxo Smith Kline. Y.Ko. has received speaking fees from AbbVie, Ayumi Pharmaceutical Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Glaxo Smith Kline, Gilead Sciences, Pfizer and Taisyo. Y. Ka. has received research grants from AbbVie, Eisai, Sanofi, Chugai, Mitsubishi-Tanabe, Taisho, and has received scholarship grant from Asahi-Kasei, Eisai, Boehringer Ingelheim, Taisho, and has received speaking fees from AbbVie, Asahi-Kasei, Astellas, Ayumi Pharmaceutical Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Pfizer, UCB, Gilead Sciences. S. W., K.Y., K.S., S.I., R.I., Y.M., W.A. declare no conflict of interest.